Solid Tumor Cancers
4
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors